DUBLIN–(BUSINESS WIRE)–The “Uveitis (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Uveitis – Drugs In Development, 2021, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.
Report Highlights
Uveitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 8, 8, 1, 1, 47 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Uveitis – Overview
- Uveitis – Therapeutics Development
- Uveitis – Therapeutics Assessment
- Uveitis – Companies Involved in Therapeutics Development
- Uveitis – Drug Profiles
- Uveitis – Dormant Projects
- Uveitis – Discontinued Products
- Uveitis – Product Development Milestones
- Appendix
Companies Mentioned
- Aciont Inc
- Active Biotech AB
- Aerie Pharmaceuticals Inc
- Afecta Pharmaceuticals Inc
- Affibody AB
- Akari Therapeutics Plc
- Aldeyra Therapeutics Inc
- Alpine Immune Sciences Inc
- Alvotech ehf
- Apidel SA
- Apitope International NV
- Avirmax Inc
- BioMarck Pharmaceuticals Ltd
- Bonac Corp
- Cellivery Therapeutics Inc
- Chugai Pharmaceutical Co Ltd
- Dobecure SL
- E&B Technologies LLC
- Elasmogen Ltd
- Enzo Biochem Inc
- EyeGate Pharmaceuticals Inc
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- HanAll Biopharma Co Ltd
- Hengenix Biotech Inc
- iCELL Biotechnology Co Ltd
- Idogen AB
- InSight Biopharmaceuticals Ltd
- Juvenescence UK Ltd
- Kodiak Sciences Inc
- Kriya Therapeutics Inc
- Kubota Vision Inc
- Kv1.3 Therapeutics
- MetrioPharm AG
- Mitotech SA
- Naegis Pharmaceuticals Inc
- NeuClone Pty Ltd
- Novaliq GmbH
- Novartis AG
- Oculis SA
- OKYO Pharma Ltd
- OncoNOx ApS
- ONL Therapeutics Inc
- Orchid Pharma Ltd
- OSE Immunotherapeutics
- Oxular Ltd
- Palatin Technologies Inc
- Panag Pharma Inc
- Pharmapraxis
- Re-Pharm Ltd
- Reven Pharmaceuticals Inc
- Revolo Biotherapeutics Ltd
- RiniSight Inc
- Ripple therapeutics Corp
- Santen Pharmaceutical Co Ltd
- SFA Therapeutics LLC
- Skye Bioscience Inc
- Sol-Gel Technologies Ltd
- Sparrow Pharmaceuticals Inc
- Tarsius Pharma Ltd
- Tianjin Pharmaceuticals Group Co Ltd
- Valitor Inc
- Vyome Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/r/2tomd5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900